Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2002 Oct 8;90(3):113–132. doi: 10.1016/S0165-2427(02)00227-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2002 Elsevier Science B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — FIV immunoblot and commercial FIV test results of cats immunized with the dual-subtype FIV vaccine or experimentally infected with FIV_PET (20 CID₅₀). Sera tested for FIV antibodies were from cats (two each) experimentally immunized with two different sources of dual-subtype FIV vaccine (immunoblot/Snap Combo lanes A, B, C and D) or experimentally infected with FIV (immunoblot/Snap Combo lanes E and F). These sera were tested for the presence of FIV antibodies using immunoblot analysis and commercial Idexx Snap^TM Combo (FeLV and FIV) Test Kit. The immunoblot analysis was performed at serum dilution of 1:100 using a published method (Pu et al., 2001) and the Snap test was performed as recommended by the Idexx Laboratories, Inc. Dual-subtype FIV vaccine produced by Fort Dodge Animal Health commercial company (USDA approved product) (lanes A and B) and those produced by our laboratory (lanes C and D) are shown for comparison. Immunogenicity and efficacy of our dual-subtype FIV vaccine has been previously reported (Pu et al., 2001). Both Snap test and immunoblot results demonstrate that vaccinated cats will develop antibodies reactive to current FIV diagnostics. Both vaccinations induced antibodies to the full spectrum of FIV antigens, including antibodies to the envelope (gp95). Interestingly, the cats immunized with the USDA approved dual-subtype FIV vaccine had more consistent and long-lasting antibodies to the envelope compared to cats immunized with our experimental dual-subtype FIV vaccine (2 of 2 cats vs. 1 of 2 cats positive after 1 year post-vaccination).